Evidences in tumorigenicity of HCC cells with stable TTK overexpression and knockdown indicated that TTK contribute to sorafenib resistance at later stage of hepatocarcinogenesis, which may explain that sorafenib was beneficial to most HCC patients and acquired resistance could only developed with prolong treatment. The gene discussed is TTK; the disease is hepatocellular carcinoma.